AMIGOS-2 study |
07/08/2018 |
CIGB |
CERVICONC-II-300 study |
07/08/2018 |
CIGB |
Jusvinza in Severe Patients with Acquired Community Pneumonia |
14/10/2022 |
CIGB |
COURAGE-2 Study |
14/03/2019 |
CIGB |
ATENEA-Co-300 study |
28/05/2020 |
CIGB |
AVATAR-2020 |
01/03/2021 |
CIGB |
DALIA Study |
11/08/2020 |
CIGB |
Safety and immunogenicity of the CIGB 2020. |
14/07/2020 |
CIGB |
ABDALA Clinical Study |
26/11/2020 |
CIGB |
MAMBISA Study |
26/11/2020 |
CIGB |
CIGB2020- ARI elderly contacts |
11/03/2021 |
CIGB |
ABDALA-Intervention |
27/03/2021 |
CIGB |
CIGB-Mambisa/Abdala in convalescents |
09/07/2021 |
CIGB |
Evaluation of the safety and immunogenicity of the vaccine candidate "ABDALA" in children and adolescents |
01/07/2021 |
CIGB |
MEÑIQUE Study |
03/09/2021 |
CIGB |
Jusvinza in rheumatoid arthritis |
20/04/2022 |
CIGB |
Nasal recombinant human interferon alfa-2b in ARI |
06/12/2022 |
CIGB |
Nasalferon in ARI |
29/07/2022 |
CIGB |
Exploratory study to evaluate the effect and safety of CIGB 500 in seriously ill patients with shock |
06/07/2023 |
CIGB |
Efficacy and safety of Jusvinza treatment in patients with acute respiratory distress syndrome. Phase II/III |
24/04/2023 |
CIGB |